Risk of CIMP+ and CIMP− colorectal cancer (CRC) according to the methylenetetrahydrofolate reductase (MTHFR ) genotype
| Females* (n=118) | Males* (n=109) | |
|---|---|---|
| *Odds ratio and 95% confidence interval for frequency of the CT or TT genotype in CRC patients compared with age matched control group. | ||
| †Defined as having two or more CpG sites methylated. | ||
| ‡p=0.037. | ||
| CIMP+, CpG island methylator phenotype. | ||
| Controls v all CRC | 1.13 (0.75–1.71) | 0.92 (0.60–1.39) |
| Controls v CIMP+† | 2.17 (1.03–4.57)‡ | 0.68 (0.32–1.42) |
| Controls v CIMP− | 0.84 (0.52–1.35)† | 1.03 (0.60–1.39) |